C WorldWide Group’s Regulus Therapeutics RGLS Stock Holding History

C WorldWide Group’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,333	Closed	-$1.4M	–	129
2015 Q4	$1.4M	Sell	1,333 -1,167	-47%	-$1.17M	0.02%	97
2015 Q3	$1.96M	Buy	2,500 +1,333	+114%	+$1.37M	0.03%	84
2015 Q2	$1.53M	Buy	+1,167	New	+$1.88M	0.02%	95

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

C WorldWide Group's RGLS Position: Q1 2016 in Review

C WorldWide Group sold out of Regulus Therapeutics (RGLS) in Q1 2016, closing a stake of 1,333 shares — an estimated $1.4M sold.

C WorldWide Group first reported a position in RGLS in Q2 2015 and held it in 3 quarters. The position peaked at $1.96M in Q3 2015. 101 funds tracked by Wall St. Rank hold RGLS as of Q1 2016.

C WorldWide Group reported no remaining Regulus Therapeutics position as of Q1 2016 after selling out during the quarter.
C WorldWide Group sold 1,333 Regulus Therapeutics shares in Q1 2016, an estimated $1.4M.
C WorldWide Group first reported a position in Regulus Therapeutics in Q2 2015 and held it in 3 quarters.
C WorldWide Group's Regulus Therapeutics position peaked at $1.96M in Q3 2015.
101 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2016.

Based on C WorldWide Group's 13F filing for Q1 2016, filed 4 May 2016.